TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2361638

Group type: EXPERIMENTAL
Intervention: Metronidazole tablets 500 mg 3 times daily for 10 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (same regimen)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Metronidazole (repeated treatments, once or twice)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Follow-up after successful treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Successful treatment
Number of subjects: 42
Study: 58199

Group type: EXPERIMENTAL
Intervention: Heparin alone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Heparin and D.H.E.
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Heparin alone and Heparin and D.H.E.
Number of subjects: 84
Study: 29562851

Group type: EXPERIMENTAL
Intervention: World Health Organization Adult ADHD Self‐Report Scale screener with standard generic feedback
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 157
Study: 26582579

Group type: EXPERIMENTAL
Intervention: Natural mineral water (500 mL)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo water
Number of subjects: 106
Study: 26053679

Group type: EXPERIMENTAL
Intervention: Single-dose antihelminthic treatment with 400 mg albendazole
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 23786864

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Late enteral nutrition
Number of subjects: 24
Study: 20888884

Group type: EXPERIMENTAL
Intervention: Filtek Z350 (nanofill composite)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Esthet‐X (nanohybrid composite)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Filtek Z250 (control composite)
Number of subjects: 41
Study: 17698301

Group type: EXPERIMENTAL
Intervention: Modified version of the Mother‐Infant Transaction Program
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study: 16432294

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg via Easyhaler
Number of subjects: 67

Group type: COMPARATOR
Intervention: Formoterol 12 microg via Aerolizer
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg via Easyhaler
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 12967078

Group type: EXPERIMENTAL
Intervention: Z100/Single Bond
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Freedom/Stae
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vitremer/Primer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Durafill/Durafill Bond
Number of subjects: 60
Study: 10710871

Group type: EXPERIMENTAL
Intervention: 0.3% Ofloxacin otic solution (OFLX) 6 drops twice daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral Amoxycillin 500 mg three times daily plus 1% Chloramphenicol ear drop at 3 drops three times daily (AMOX + CRP)
Number of subjects: 80
Study: 8703458

Group type: EXPERIMENTAL
Intervention: Propofol plus saline
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol plus succinylcholine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Thiamylal plus succinylcholine
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propofol without succinylcholine
Number of subjects: 56
Study: 1286717

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation of the posterior parietal cortex, applied 80 ms after target movement in 70% of trials.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control, unstimulated trials.
Number of subjects: 0
Study: 3872082

Group type: EXPERIMENTAL
Intervention: Transcutaneous neural stimulation (TNS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo unit
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no TNS unit)
Number of subjects: 90
Study: 31963702

Group type: EXPERIMENTAL
Intervention: Fortified formula with dairy-based microencapsulated high DHA tuna oil powder
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fortified formula with allergenic-free microencapsulated high DHA tuna oil powder
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfortified formula plus high DHA tuna oil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unfortified formula
Number of subjects: 60
Study: 30397735

Group type: EXPERIMENTAL
Intervention: iRoot SP sealer
Number of subjects: 160

Group type: COMPARATOR
Intervention: AH Plus sealer
Number of subjects: 160
Study: 28002181

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo drink (no caffeine)
Number of subjects: 16
Study: 25959878

Group type: EXPERIMENTAL
Intervention: Resorbable collagen membrane (Bio-Gide, Geistlich Pharma AG) placement after extraction of L3M
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (only suture) after extraction of L3M
Number of subjects: 60
Study: 24377413

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual-care program
Number of subjects: 75
Study: 21965459

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (EEF)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Delayed enteral feeding (DEF)
Number of subjects: 59
Study: 20671225

Group type: EXPERIMENTAL
Intervention: Fluvastatin combined with benazepril-valsartan therapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Benazepril-valsartan therapy alone
Number of subjects: 186
Study: 17438421

Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) instrument 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stratus optical coherence tomography (OCT) instrument 2
Number of subjects: 20
Study: 19810298

Group type: EXPERIMENTAL
Intervention: Zinc sulphate powder, equivalent to 20 mg elemental zinc
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 242
Study: 12476650

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stent (drug-eluting stent)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (non-drug-eluting stent)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stent (TAXUS-I trial)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Control group (TAXUS-I trial)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated stents (ASPECT and ELUTES trials)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated stents (RAVEL and SIRIUS trials)
Number of subjects: 266
Study: 10467200

Group type: EXPERIMENTAL
Intervention: Neurosurgical evacuation
Number of subjects: 268

Group type: COMPARATOR
Intervention: No neurosurgical evacuation (Control)
Number of subjects: 268
Study: 7600552

Group type: EXPERIMENTAL
Intervention: Preparatory patient education (two structured teaching interventions incorporating sensory and procedural information)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard information (control group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preparatory patient education
Number of subjects: 50
Study: 2360387

Group type: EXPERIMENTAL
Intervention: Lidocaine as laryngotracheal spray (1 mg/kg BW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine as transtracheal injection (1 mg/kg BW)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine as intravenous injection (1 mg/kg BW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 80
Study: 118805

Group type: EXPERIMENTAL
Intervention: Hexamethylmelamine (HMM) alone, 300 mg/m2/day x 14 days every 21 days
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: HOM regimen (HMM 200 mg/m2/day x 21 days, vincristine 1.5 mg on Days 1, 8, and 15, mitomycin C 12 mg/m2 once every 6 weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hexamethylmelamine (HMM) alone
Number of subjects: 53

Group type: COMPARATOR
Intervention: HOM regimen
Number of subjects: 53
Study: 31653669

Group type: EXPERIMENTAL
Intervention: Atropine (0.01%) eye-drops, one drop in each eye every day for 2 years
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo eye-drops, one drop in each eye every day for 2 years
Number of subjects: 289
Study: 31484647

Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Bortezomib + Lenalidomide + Dexamethasone (VRD)
Number of subjects: 458
Study: 28186634

Group type: EXPERIMENTAL
Intervention: Resource Diary (RD) intervention over 4 weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study: 25841542

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 23478192

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus education
Number of subjects: 24

Group type: COMPARATOR
Intervention: Education only
Number of subjects: 24
Study: 21120738

Group type: EXPERIMENTAL
Intervention: Educational intervention about the regulation of dietary supplements under the DSHEA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no educational intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDA approval information manipulation
Number of subjects: 0
Study: 19486798

Group type: EXPERIMENTAL
Intervention: Thin-flap LASIK/sub-Bowman keratomileusis (SBK)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 50
Study: 18050183

Group type: EXPERIMENTAL
Intervention: Etanercept treatment in group A (G/A genotype)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Etanercept treatment in group G (G/G genotype)
Number of subjects: 86
Study: 15758606

Group type: EXPERIMENTAL
Intervention: ST-waveform analysis of the fetal electrocardiogram (ECG)
Number of subjects: 8000

Group type: EXPERIMENTAL
Intervention: Automated ST analysis added to fetal heart rate trace
Number of subjects: 8000
Study: 11888512

Group type: EXPERIMENTAL
Intervention: HMG CoA RI therapy (pravastatin 40 mg QD or simvastatin 20 mg QD)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9475818

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 100 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8545877

Group type: EXPERIMENTAL
Intervention: Ganciclovir treatment
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 149
Study: 759413

Group type: EXPERIMENTAL
Intervention: Hearing aid usage in Group A (mean age 27.6 years, N=50)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hearing aid usage in Group B (mean age 75.06 years, N=50)
Number of subjects: 50
Study: 31133474

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 65)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (control group, n = 65)
Number of subjects: 130
Study: 29392372

Group type: EXPERIMENTAL
Intervention: Alcohol (target BrAC of 0.080%)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27430340

Group type: EXPERIMENTAL
Intervention: Acupuncture (AG)
Number of subjects: 250

Group type: COMPARATOR
Intervention: No Acupuncture (NAG)
Number of subjects: 250
Study: 25344738

Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type I IFN or CXCL10
Number of subjects: 0
Study: 22955258

Group type: EXPERIMENTAL
Intervention: pAMPK-positive group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: pAMPK-negative group
Number of subjects: 74
Study: 20100992

Group type: EXPERIMENTAL
Intervention: Phentolamine (alpha‐adrenoceptor antagonist)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Nicardipine (calcium channel blocker)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Norepinephrine increase during phentolamine infusion
Number of subjects: 13
Study: 18068060

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30 mg/kg bolus, 10 mg/kg/h infusion for 48 hours)
Number of subjects: 24
Study: 16025972

Group type: EXPERIMENTAL
Intervention: MTX plus TGP
Number of subjects: 61

Group type: COMPARATOR
Intervention: MTX
Number of subjects: 61
Study: 11994882

Group type: EXPERIMENTAL
Intervention: 2% lavender oil aromatherapy stream administered for a two hour period every other day for a total of ten treatment sessions.
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (water) administered for a two hour period every other day for a total of ten treatment sessions.
Number of subjects: 15
Study: 10327088

Group type: EXPERIMENTAL
Intervention: Forearm suspended by a balancer
Number of subjects: 12

Group type: COMPARATOR
Intervention: Forearm not suspended (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher work area position
Number of subjects: 12
Study: 8590749

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (exercise training, psychosocial support, education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation for surgical patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modification of risk factors in patients with known coronary disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent studies on cardiac rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life and return to work after bypass surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncardiac complications of surgery
Number of subjects: 0
Study: 2187896

Group type: EXPERIMENTAL
Intervention: Surgical wadding of the axillary fossa with the use of proximate muscular tissue
Number of subjects: 53
Study: 380732

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (CP) weekly subcutaneous injections in addition to standard treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 26
Study: 30859184

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg q8h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 50 mg q6h
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both dosing regimens
Number of subjects: 12
Study: 25683204

Group type: EXPERIMENTAL
Intervention: Risk score-based screening starting at age 47 for top 5% risk group, screening every four years starting at age 55 for median group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shortened interscreening interval for high risk group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard screening every four years starting at age 55 for median risk group
Number of subjects: 0
Study: 23915086

Group type: EXPERIMENTAL
Intervention: Learning of the base rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Learning of the repetition rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interaction of base rate and repetition rate learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Event-related potentials and stimulus discriminability manipulations
Number of subjects: 0
Study: 21324590

Group type: EXPERIMENTAL
Intervention: CST plus sertraline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CST plus placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 0
Study: 19270316

Group type: EXPERIMENTAL
Intervention: High serum YKL-40 concentration
Number of subjects: 4298
Study: 17299655

Group type: EXPERIMENTAL
Intervention: Perioperative improvements including thorough preoperative haematological checks, administration of inhibitors of fibrinolysis (aprotinin, ε‐aminocaproic acid), minimization of extracorporeal circulation (ECC), and postoperative recovery measures (i.v. iron and recombinant human erythropoietin).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern blood product quality and real-time monitoring of haemorrhagic/thrombogenic risk using thrombelastography analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Setting transfusion trigger based on haemoglobin concentration to as low as 70 g/l in suitable patients.
Number of subjects: 0
Study: 15188791

Group type: EXPERIMENTAL
Intervention: Antenatal pharmacologic magnesium sulfate (MgSO4)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dosage magnesium sulfate (MgSO4) for tocolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dosage magnesium sulfate (MgSO4)
Number of subjects: 0
Study: 11721504

Group type: EXPERIMENTAL
Intervention: montelukast 10mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: montelukast (addition to standard therapy)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (standard therapy: intra-nasal corticosteroids)
Number of subjects: 32
Study: 9220522

Group type: EXPERIMENTAL
Intervention: Capsaicin inhalation before hypertonic saline (HS) challenge
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hypertonic saline (HS) challenge alone
Number of subjects: 21
Study: 8116057

Group type: EXPERIMENTAL
Intervention: Daily proguanil (PROG)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Once weekly chloroquine (CQ)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Two drug combination (CQ+PROG)
Number of subjects: 170
Study: 3321924

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31122144

Group type: EXPERIMENTAL
Intervention: Standard practice of titrating heparin to activated partial thromboplastin times goal of 45-55 seconds (Arm 1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-titrating weight-based heparin infusion (10 units/kg/h) (Arm 2)
Number of subjects: 10
Study: 31601214

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 911
Study: 26287803

Group type: EXPERIMENTAL
Intervention: e-learning course
Number of subjects: 39

Group type: COMPARATOR
Intervention: lecture-based course
Number of subjects: 39
Study: 25376670

Group type: EXPERIMENTAL
Intervention: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon), treated three times a week for a total of 10 sessions.
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tri-length laser therapy (iLux-Triax) and tecar therapy (Pharon) in patients with low-back pain and leg pain.
Number of subjects: 66
Study: 24187727

Group type: EXPERIMENTAL
Intervention: Faculty-designed intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual honor code exposure
Number of subjects: 346
Study: 21471553

Group type: EXPERIMENTAL
Intervention: Preterm subjects
Number of subjects: 49

Group type: COMPARATOR
Intervention: Term subjects
Number of subjects: 49
Study: 18637086

Group type: EXPERIMENTAL
Intervention: Flow permissive time ≤ 2.5 s
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 30 mmHg peristaltic amplitude
Number of subjects: 50
Study: 16926581

Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment consisting of education, exercise and stretch, goal setting, medication management, and cognitive and behavioral techniques.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Interdisciplinary treatment
Number of subjects: 99
Study: 15592276

Group type: EXPERIMENTAL
Intervention: Goserelin injection (3.6 mg/month)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 147
Study: 11697019

Group type: EXPERIMENTAL
Intervention: Self-reported adherence to HAART (measured by PMAQ-V1.0)
Number of subjects: 194
Study: 9018388

Group type: EXPERIMENTAL
Intervention: Paroxetine and Fluoxetine (SSRIs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study: 8276043

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg taken once daily with breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg taken once daily with evening meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2437417

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both drugs (Acyclovir and Inosine Pranobex)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Inosine Pranobex
Number of subjects: 77
Study: 31973631

Group type: COMPARATOR
Intervention: Local vibration
Number of subjects: 24

Group type: COMPARATOR
Intervention: Graduated compression stockings
Number of subjects: 24

Group type: COMPARATOR
Intervention: Graduated compression stockings + local vibration
Number of subjects: 24
Study: 29870501

Group type: EXPERIMENTAL
Intervention: Multisession behavioral intervention plus antiretrovirals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multisession behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard HIV counseling
Number of subjects: 0
Study: 27615712

Group type: EXPERIMENTAL
Intervention: TA-TAVI
Number of subjects: 58

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: TA-TAVI and SAVR
Number of subjects: 58
Study: 25078372

Group type: EXPERIMENTAL
Intervention: scFOS-supplemented formula (4 g/L scFOS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: placebo-supplemented formula (4 g/L maltodextrins)
Number of subjects: 61
Study: 21270839

Group type: EXPERIMENTAL
Intervention: cis‐9, trans‐11 CLA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: industrial trans fatty acids
Number of subjects: 61

Group type: COMPARATOR
Intervention: oleic acid
Number of subjects: 61
Study: 20723569

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isometric voluntary muscular contraction (VOL)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PRE condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: POST condition
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both NMES and VOL
Number of subjects: 15
Study: 18222648

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 16319311

Group type: EXPERIMENTAL
Intervention: Unilateral temporal lobectomy patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Patients with declarative memory of contingencies
Number of subjects: 62
Study: 12736485

Group type: EXPERIMENTAL
Intervention: hANP (25 microg intracoronary injection + 0.025 microg x kg(‐1) x min(‐1) intravenous infusion for 1 week)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 19